Difference between revisions of "Part:BBa K2549003"
(→Usage and Biology) |
|||
(One intermediate revision by the same user not shown) | |||
Line 29: | Line 29: | ||
[[File:LaGg.png|none|300px|thumb|As stated by Fridy PC et al: ''Mapping of nanobody binding epitopes on GFP by NMR. Binding epitopes of the 11 highest-affinity nanobodies on GFPuv are shown in three groups according to their location. For each nanobody, two opposite sides of GFPuv are shown (via a 180° rotation along a vertical axis), with the binding site of the respective nanobody colored green. All GFPuv molecules are represented in space-filling mode and have the same orientation in all panels. Maps below Group III in the right column show the GFP-Trap nanobody’s binding epitope (top) and GFPuv’s homodimerization interface (center). For reference, the ribbon diagram at bottom right depicts secondary structure elements of GFPuv, in the same orientation as other panels.'' Please pay attention to LaG-16, LaG-17, LaG-2.]] | [[File:LaGg.png|none|300px|thumb|As stated by Fridy PC et al: ''Mapping of nanobody binding epitopes on GFP by NMR. Binding epitopes of the 11 highest-affinity nanobodies on GFPuv are shown in three groups according to their location. For each nanobody, two opposite sides of GFPuv are shown (via a 180° rotation along a vertical axis), with the binding site of the respective nanobody colored green. All GFPuv molecules are represented in space-filling mode and have the same orientation in all panels. Maps below Group III in the right column show the GFP-Trap nanobody’s binding epitope (top) and GFPuv’s homodimerization interface (center). For reference, the ribbon diagram at bottom right depicts secondary structure elements of GFPuv, in the same orientation as other panels.'' Please pay attention to LaG-16, LaG-17, LaG-2.]] | ||
− | Note: [[Part:BBa_K2549002]], [[Part:BBa_K2549003]] and [[Part: | + | Note: [[Part:BBa_K2549002]], [[Part:BBa_K2549003]] and [[Part:BBa_K2549004]] have the same '''Biology''' section. |
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display | ||
===Functional Parameters=== | ===Functional Parameters=== | ||
− | <partinfo> | + | <partinfo>BBa_K2549003 parameters</partinfo> |
--> | --> | ||
===References=== | ===References=== |
Latest revision as of 16:59, 17 October 2018
anti-GFP (LaG16)
Anti-GFP (LaG16) is a readily expressible recombinant nanobody which has a high affinity and high specificity against GFP[1]. It was used as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against GFP. Two copies of LaG16 joined to form LaG2 (Part:BBa_K2549002) using a flexible glycine-rich peptide linker, which is a dimerized, ultra-high affinity antibody against GFP. This nanobody recognizes our surEGFP (Part:BBa_K2446051) expressing cells.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 243
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Biology
Data reported in Fridy PC et al, 2014
Please refer the original article for more details.
We thank the authors carefully documented all the sequences. We used these information, reverse translated and performed codon optimization for better expression in human.
Note: Part:BBa_K2549002, Part:BBa_K2549003 and Part:BBa_K2549004 have the same Biology section.
References
- ↑ A robust pipeline for rapid production of versatile nanobody repertoires. Fridy PC, Li Y, Keegan S, ..., Chait BT, Rout MP. Nat Methods, 2014 Dec;11(12):1253-60 PMID: 25362362; DOI: 10.1038/nmeth.3170